CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update


- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -

Continued here:
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Related Posts